Bryant D. Lim
Equibles does not estimate personal net worth.
Get an email with a short summary when Prelude Therapeutics Inc publishes a filing, an earnings call transcript or a press release.
Get PRLD alertsAbout Bryant D. Lim
Bryant D. Lim is recorded as CFO at Prelude Therapeutics Inc (PRLD). The newest filing on record that lists Bryant D. Lim as CFO at Prelude Therapeutics Inc (PRLD) is dated April 29, 2026. Prelude Therapeutics Inc reported in an 8-K filed February 5, 2025 that Bryant D. Lim was appointed permanent Chief Financial Officer, effective February 3, 2025. Prelude Therapeutics Inc reported in an 8-K filed April 10, 2024 that Bryant D. Lim was appointed interim Chief Financial Officer, effective April 8, 2024. The proxy statement of Prelude Therapeutics Inc reports total compensation of $847,397 for Bryant D. Lim in fiscal 2025, including a base salary of $477,500. Disclosed compensation is on record for 3 fiscal years. Prelude Therapeutics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Prelude Therapeutics Inc includes Krishna Vaddi (CEO and Board Member), Julian C. Baker (Board Member), Katina Dorton (Board Member) and 2 others.
“On February 3, 2025 (the "Effective Date"), the Board approved the appointment of Mr. Lim as the Company's permanent Chief Financial Officer, effective as of the Effective Date.”
“Effective as of the Effective Date, the Board of Directors of the Company appointed Bryant D. Lim, the Company’s Chief Legal Officer and Corporate Secretary, as its interim Chief Financial Officer.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 29, 2026
-
Prelude Therapeutics Inc (PRLD)
Proxy statement
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Prelude Therapeutics Inc
- Krishna Vaddi CEO, Board Member
- Julian C. Baker Board Member
- Katina Dorton Board Member
- Martin Babler Board Member
- Paul Scherer, M.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Prelude Therapeutics Inc (PRLD) | Chief Legal Officer, Corporate Secretary, and Chief Financial Officer | $477,500 | $847,397 |
| 2024 | Prelude Therapeutics Inc (PRLD) | Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer | $444,167 | $1,202,912 |
| 2023 | Prelude Therapeutics Inc (PRLD) | Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer | $359,282 | $1,614,766 |